IVBXF
Innovent Biologics, Inc.
Price Chart
Latest Quote
$10.29
+0.48 (+4.85%)
Current Price
| Previous Close | $9.81 |
| Open | $9.50 |
| Day High | $9.79 |
| Day Low | $9.50 |
| Volume | 450 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 1.73B |
| Total Debt | $414.74M |
| Cash Equivalents | $2.69B |
| Revenue | $1.92B |
| Net Income | $119.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $17.85B |
| P/E Ratio | 147.00 |
| EPS (TTM) | $0.07 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.43B |
| Sales | $1.92B |
| Income | $119.83M |
| Book/sh | $1.65 |
| Cash/sh | $10.51 |
| Employees | 8K |
Financial Ratios
| Quick Ratio | 2.38 |
| Current Ratio | 2.62 |
| Debt/Eq | 14.55 |
Returns & Margins
| ROA | 1.56% |
| ROE | 5.01% |
| Gross Margin | 76.66% |
| Operating Margin | -0.56% |
| Profit Margin | 6.24% |
Ownership
| Insider Ownership | 6.26% |
| Institutional Ownership | 56.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 1.80 |
| P/S | 1.37 |
| P/B | 6.25 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $9.91 |
| SMA50 | $10.38 |
| SMA200 | $11.01 |
| RSI | 53.30 |
| ATR | 0.4060 |
| Shares Float | 1.61B |
| Volatility | 0.21 |
| Rel Volume | 0.04 |
Performance History
| Week | +2.37% |
| Month | -0.48% |
| Quarter | +5.54% |
| 6 Months | -5.07% |
| YTD | -4.93% |
| Year | +1.88% |
| 3 Years | +123.21% |
| 5 Years | -10.13% |
| 10 Years | +226.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $10.29 | 308 |
| 2026-06-23 | $9.81 | 0 |
| 2026-06-22 | $9.81 | 2,004 |
| 2026-06-18 | $9.96 | 408 |
| 2026-06-17 | $9.56 | 6,572 |
| 2026-06-16 | $10.05 | 894 |
| 2026-06-15 | $9.62 | 1,300 |
| 2026-06-12 | $9.79 | 1,642 |
| 2026-06-11 | $9.60 | 333 |
| 2026-06-10 | $9.10 | 0 |
| 2026-06-09 | $9.10 | 755 |
| 2026-06-08 | $9.10 | 1,134 |
| 2026-06-05 | $10.09 | 794 |
| 2026-06-04 | $10.24 | 2,124 |
| 2026-06-03 | $10.01 | 1,254 |
| 2026-06-02 | $10.43 | 6,582 |
| 2026-06-01 | $11.30 | 120,990 |
| 2026-05-29 | $10.77 | 10,274 |
| 2026-05-28 | $9.55 | 331 |
| 2026-05-27 | $10.07 | 359 |
| 2026-05-26 | $10.34 | 0 |
About Innovent Biologics, Inc.
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
đ° Latest News
Novo Nordisk to File Oral Wegovy in China
GuruFocus.com âĸ 2026-06-16T18:52:24ZGlobal Value Stocks Trading Below Estimated Worth In June 2026
Simply Wall St. âĸ 2026-06-15T09:38:25Z
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 29.4%
Simply Wall St. âĸ 2026-06-15T04:38:31Z
3 Asian Stocks Estimated To Be Priced Below Intrinsic Value In June 2026
Simply Wall St. âĸ 2026-06-05T04:37:48Z
3 Asian Stocks Estimated To Be Up To 43.2% Below Intrinsic Value
Simply Wall St. âĸ 2026-06-04T22:34:32Z
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?
Insider Monkey âĸ 2026-06-02T14:11:40Z
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
Insider Monkey âĸ 2026-06-02T13:58:04Z
Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
Simply Wall St. âĸ 2026-06-01T15:11:51Z
Asian Market's May 2026 Stocks Priced Below Estimated Value
Simply Wall St. âĸ 2026-05-31T22:34:19Z
Growing US reliance on Chinese biotechs prompts national security fears
Financial Times âĸ 2026-05-31T12:00:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,510,210,000 | $1,136,266,000 | $930,990,000 | $505,337,000 |
| Cost Of Revenue | $1,510,210,000 | $1,136,266,000 | $930,990,000 | $505,337,000 |
| Total Revenue | $9,421,888,000 | $6,206,070,000 | $4,556,380,000 | $4,269,729,000 |
| Operating Revenue | $9,421,888,000 | $6,206,070,000 | $4,556,380,000 | $4,269,729,000 |
| Expenses | ||||
| Interest Expense | $67,647,000 | $98,624,000 | $101,698,000 | $62,464,000 |
| Total Expenses | $9,163,769,000 | $7,115,280,000 | $7,138,265,000 | $6,208,876,000 |
| Other Non Operating Income Expenses | $-937,861,000 | $-680,093,000 | $-433,639,000 | $-717,419,000 |
| Net Non Operating Interest Income Expense | $355,807,000 | $354,213,000 | $87,839,000 | $89,291,000 |
| Interest Expense Non Operating | $67,647,000 | $98,624,000 | $101,698,000 | $62,464,000 |
| Operating Expense | $7,653,559,000 | $5,979,014,000 | $6,207,275,000 | $5,703,539,000 |
| Selling And Marketing Expense | $4,346,892,000 | $3,100,693,000 | $2,590,765,000 | $2,620,142,000 |
| General And Administrative Expense | $738,046,000 | $750,278,000 | $835,488,000 | $806,010,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Net Interest Income | $355,807,000 | $354,213,000 | $87,839,000 | $89,291,000 |
| Interest Income | $423,454,000 | $452,837,000 | $189,537,000 | $151,755,000 |
| Normalized Income | $-211,664,000 | $-1,054,728,840 | $-2,183,141,500 | $-2,821,986,000 |
| Net Income From Continuing And Discontinued Operation | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Net Income Common Stockholders | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Net Income | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Net Income Including Noncontrolling Interests | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Net Income Continuous Operations | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Pretax Income | $-78,621,000 | $-1,144,411,000 | $-2,170,469,000 | $-2,641,717,000 |
| Special Income Charges | $-22,987,000 | $-952,000 | $60,000 | $-709,000 |
| Interest Income Non Operating | $423,454,000 | $452,837,000 | $189,537,000 | $151,755,000 |
| Operating Income | $258,119,000 | $-909,210,000 | $-2,581,885,000 | $-1,939,147,000 |
| Gross Profit | $7,911,678,000 | $5,069,804,000 | $3,625,390,000 | $3,764,392,000 |
| Per Share | ||||
| Diluted EPS | $-0.06 | $-0.66 | $-1.46 | $-1.88 |
| Basic EPS | $-0.06 | $-0.66 | $-1.46 | $-1.88 |
| Other | ||||
| Tax Effect Of Unusual Items | $39,011,000 | $3,039,160 | $1,290,500 | $31,077,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $252,750,000 | $-690,539,000 | $-1,754,511,000 | $-2,498,814,000 |
| Total Unusual Items | $156,044,000 | $29,855,000 | $5,162,000 | $124,308,000 |
| Total Unusual Items Excluding Goodwill | $156,044,000 | $29,855,000 | $5,162,000 | $124,308,000 |
| Reconciled Depreciation | $419,768,000 | $385,103,000 | $319,422,000 | $204,747,000 |
| EBITDA (Bullshit earnings) | $408,794,000 | $-660,684,000 | $-1,749,349,000 | $-2,374,506,000 |
| EBIT | $-10,974,000 | $-1,045,787,000 | $-2,068,771,000 | $-2,579,253,000 |
| Diluted Average Shares | $1,627,460,846 | $1,559,637,004 | $1,490,123,192 | $1,455,605,751 |
| Basic Average Shares | $1,627,460,846 | $1,559,637,004 | $1,490,123,192 | $1,455,605,751 |
| Diluted NI Availto Com Stockholders | $-94,631,000 | $-1,027,913,000 | $-2,179,270,000 | $-2,728,755,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Tax Provision | $16,010,000 | $-116,498,000 | $8,801,000 | $87,038,000 |
| Other Special Charges | $22,987,000 | $952,000 | $-60,000 | $709,000 |
| Research And Development | $2,681,074,000 | $2,227,556,000 | $2,871,220,000 | $2,322,513,000 |
| Selling General And Administration | $5,084,938,000 | $3,850,971,000 | $3,426,253,000 | $3,426,152,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,480,647,000 | $10,981,732,000 | $9,531,786,000 | $9,558,203,000 |
| Total Assets | $21,602,602,000 | $20,627,360,000 | $17,588,845,000 | $16,243,713,000 |
| Total Non Current Assets | $11,329,765,000 | $7,199,375,000 | $6,082,137,000 | $4,692,864,000 |
| Non Current Prepaid Assets | $352,363,000 | $283,116,000 | $193,058,000 | - |
| Investmentin Financial Assets | $3,041,905,000 | $794,089,000 | $630,197,000 | $417,255,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $2,255,549,000 | $575,788,000 | $427,627,000 | $213,809,000 |
| Goodwill And Other Intangible Assets | $1,637,082,000 | $1,545,849,000 | $1,198,163,000 | $772,194,000 |
| Other Intangible Assets | $1,637,082,000 | $1,545,849,000 | $1,198,163,000 | $772,194,000 |
| Current Assets | $10,272,837,000 | $13,427,985,000 | $11,506,708,000 | $11,550,849,000 |
| Inventory | $822,167,000 | $968,088,000 | $1,428,882,000 | $1,347,240,000 |
| Other Receivables | $382,523,000 | $484,377,000 | $336,521,000 | $213,261,000 |
| Accounts Receivable | $1,184,407,000 | $1,005,891,000 | $575,269,000 | $968,405,000 |
| Cash Cash Equivalents And Short Term Investments | $7,883,740,000 | $10,119,781,000 | $8,264,594,000 | $7,940,893,000 |
| Cash And Cash Equivalents | $7,508,185,000 | $2,745,693,000 | $1,016,165,000 | $1,359,408,000 |
| Cash Financial | $7,508,185,000 | $1,350,066,000 | $695,793,000 | $786,576,000 |
| Financial Assets | - | $0 | $0 | $0 |
| Restricted Cash | - | $849,848,000 | $901,442,000 | $1,074,415,000 |
| Cash Equivalents | - | $1,395,627,000 | $320,372,000 | $572,832,000 |
| Hedging Assets Current | - | - | $0 | $6,635,000 |
| Prepaid Assets | - | - | - | $213,261,000 |
| Debt | ||||
| Total Debt | $2,831,043,000 | $3,620,529,000 | $3,228,508,000 | $2,496,926,000 |
| Long Term Debt And Capital Lease Obligation | $2,417,114,000 | $2,400,199,000 | $2,314,116,000 | $2,109,653,000 |
| Long Term Debt | $2,412,354,000 | $2,326,777,000 | $2,215,433,000 | $2,023,261,000 |
| Current Debt And Capital Lease Obligation | $413,929,000 | $1,220,330,000 | $914,392,000 | $387,273,000 |
| Current Debt | $405,100,000 | $1,195,155,000 | $888,000,000 | $365,000,000 |
| Net Debt | - | $776,239,000 | $2,087,268,000 | $1,028,853,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,484,873,000 | $8,099,779,000 | $6,858,896,000 | $5,913,316,000 |
| Total Non Current Liabilities Net Minority Interest | $4,116,004,000 | $3,622,963,000 | $3,359,698,000 | $2,863,269,000 |
| Current Liabilities | $4,368,869,000 | $4,476,816,000 | $3,499,198,000 | $3,050,047,000 |
| Payables | $1,639,886,000 | $1,235,736,000 | $941,999,000 | $951,910,000 |
| Other Payable | $1,206,366,000 | $669,138,000 | $555,362,000 | $664,084,000 |
| Total Tax Payable | $75,843,000 | $194,049,000 | $61,015,000 | $92,776,000 |
| Accounts Payable | $357,677,000 | $372,549,000 | $325,622,000 | $195,050,000 |
| Equity | ||||
| Common Stock Equity | $13,117,729,000 | $12,527,581,000 | $10,729,949,000 | $10,330,397,000 |
| Total Equity Gross Minority Interest | $13,117,729,000 | $12,527,581,000 | $10,729,949,000 | $10,330,397,000 |
| Stockholders Equity | $13,117,729,000 | $12,527,581,000 | $10,729,949,000 | $10,330,397,000 |
| Other Equity Interest | $1,652,162,000 | $1,409,458,000 | $1,216,849,000 | - |
| Retained Earnings | $-15,906,368,000 | $-15,767,568,000 | $-14,739,655,000 | - |
| Long Term Equity Investment | $858,991,000 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $1,638,147,004 | $1,621,830,905 | $1,534,406,983 | $1,462,108,664 |
| Share Issued | $1,638,147,004 | $1,621,830,905 | $1,534,406,983 | $1,462,108,664 |
| Tangible Book Value | $11,480,647,000 | $10,981,732,000 | $9,531,786,000 | $9,558,203,000 |
| Invested Capital | $15,935,183,000 | $16,049,513,000 | $13,833,382,000 | $12,718,658,000 |
| Working Capital | $5,903,968,000 | $8,951,169,000 | $8,007,510,000 | $8,500,802,000 |
| Capital Lease Obligations | $13,589,000 | $98,597,000 | $125,075,000 | $108,665,000 |
| Total Capitalization | $15,530,083,000 | $14,854,358,000 | $12,945,382,000 | $12,353,658,000 |
| Additional Paid In Capital | $27,722,624,000 | $27,324,496,000 | $24,705,638,000 | - |
| Capital Stock | $113,000 | $112,000 | $105,000 | $101,000 |
| Common Stock | $113,000 | $112,000 | $105,000 | $101,000 |
| Non Current Deferred Revenue | $1,215,072,000 | $960,051,000 | $883,277,000 | $753,274,000 |
| Long Term Capital Lease Obligation | $4,760,000 | $73,422,000 | $98,683,000 | $86,392,000 |
| Long Term Provisions | $22,858,000 | - | - | - |
| Current Capital Lease Obligation | $8,829,000 | $25,175,000 | $26,392,000 | $22,273,000 |
| Available For Sale Securities | $786,356,000 | $218,301,000 | $202,570,000 | $203,446,000 |
| Investmentsin Associatesat Cost | $858,991,000 | $0 | - | - |
| Net PPE | $5,439,424,000 | $4,576,321,000 | $4,060,719,000 | $3,375,757,000 |
| Accumulated Depreciation | $-1,321,312,000 | $-1,035,627,000 | $-760,558,000 | $-516,826,000 |
| Gross PPE | $6,760,736,000 | $5,611,948,000 | $4,821,277,000 | $3,892,583,000 |
| Construction In Progress | $1,485,964,000 | $2,338,008,000 | $1,373,307,000 | $1,579,058,000 |
| Machinery Furniture Equipment | $3,133,040,000 | $2,658,379,000 | $2,523,203,000 | $1,420,090,000 |
| Buildings And Improvements | $2,141,732,000 | $615,561,000 | $628,893,000 | $607,460,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $225,168,000 | $269,065,000 | $359,527,000 | $154,825,000 |
| Work In Process | $192,143,000 | $325,101,000 | $484,606,000 | $382,728,000 |
| Raw Materials | $404,856,000 | $373,922,000 | $584,749,000 | $806,087,000 |
| Other Short Term Investments | $375,555,000 | $7,374,088,000 | $7,248,429,000 | $6,581,485,000 |
| Land And Improvements | - | $275,583,000 | $295,874,000 | $285,975,000 |
| Other Properties | - | - | $3,826,146,000 | $3,089,848,000 |
| Other Inventories | - | - | - | $3,600,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-418,388,000 | $-1,235,650,000 | $-3,300,534,000 | $-3,872,359,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,287,024,000 | $147,810,000 | $-1,918,804,000 | $-2,024,843,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,705,412,000 | $-1,383,460,000 | $-1,381,730,000 | $-1,847,516,000 |
| Investing Cash Flow | $-1,165,411,000 | $-998,662,000 | $-1,435,185,000 | $-2,698,148,000 |
| Net Other Investing Changes | $849,579,000 | $232,359,000 | $144,955,000 | $-785,962,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $84,312,000 | $2,255,116,000 | $2,131,059,000 | $3,950,520,000 |
| Financing Cash Flow | $-606,632,000 | $2,587,257,000 | $2,892,082,000 | $5,003,361,000 |
| Net Other Financing Charges | $161,924,000 | $90,893,000 | $178,473,000 | $2,000,000 |
| Net Common Stock Issuance | $84,312,000 | $2,255,116,000 | $2,131,059,000 | $3,950,520,000 |
| Common Stock Issuance | $84,312,000 | $2,255,116,000 | $2,131,059,000 | $3,950,520,000 |
| Other | ||||
| Repayment Of Debt | $-1,220,049,000 | $-917,050,000 | $-365,000,000 | $-255,000,000 |
| Issuance Of Debt | $515,571,000 | $1,335,549,000 | $1,080,172,000 | $1,463,083,000 |
| End Cash Position | $2,273,356,000 | $2,745,693,000 | $1,016,165,000 | $1,359,408,000 |
| Beginning Cash Position | $2,745,693,000 | $1,016,165,000 | $1,359,408,000 | $1,276,178,000 |
| Effect Of Exchange Rate Changes | $12,682,000 | $-6,877,000 | $118,664,000 | $-197,140,000 |
| Changes In Cash | $-485,019,000 | $1,736,405,000 | $-461,907,000 | $280,370,000 |
| Interest Paid Cff | $-122,425,000 | $-127,613,000 | $-104,884,000 | $-78,826,000 |
| Net Issuance Payments Of Debt | $-704,478,000 | $418,499,000 | $715,172,000 | $1,208,083,000 |
| Net Long Term Debt Issuance | $-704,478,000 | $418,499,000 | $715,172,000 | $1,208,083,000 |
| Long Term Debt Payments | $-1,220,049,000 | $-917,050,000 | $-365,000,000 | $-255,000,000 |
| Long Term Debt Issuance | $515,571,000 | $1,335,549,000 | $1,080,172,000 | $1,463,083,000 |
| Interest Received Cfi | $660,464,000 | $306,302,000 | $107,259,000 | $151,640,000 |
| Net Investment Purchase And Sale | $-70,312,000 | $-170,147,000 | $-305,859,000 | $-216,408,000 |
| Sale Of Investment | $10,465,272,000 | $9,244,320,000 | $10,019,845,000 | $10,121,480,000 |
| Purchase Of Investment | $-10,535,584,000 | $-9,414,467,000 | $-10,325,704,000 | $-10,337,888,000 |
| Net Business Purchase And Sale | $-900,000,000 | $0 | - | - |
| Purchase Of Business | $-900,000,000 | $0 | - | - |
| Net Intangibles Purchase And Sale | $-676,419,000 | $-262,350,000 | $-468,604,000 | $-781,882,000 |
| Purchase Of Intangibles | $-676,419,000 | $-262,350,000 | $-468,604,000 | $-781,882,000 |
| Net PPE Purchase And Sale | $-1,028,723,000 | $-1,104,826,000 | $-912,936,000 | $-1,065,536,000 |
| Sale Of PPE | $270,000 | $16,284,000 | $190,000 | $98,000 |
| Purchase Of PPE | $-1,028,993,000 | $-1,121,110,000 | $-913,126,000 | $-1,065,634,000 |
| Taxes Refund Paid | $-157,000 | $114,415,000 | $-66,099,000 | $-26,444,000 |
| Change In Working Capital | $403,755,000 | $403,389,000 | $309,908,000 | $-91,982,000 |
| Change In Other Current Assets | $-31,192,000 | $-138,627,000 | $205,041,000 | $105,432,000 |
| Change In Payable | $645,184,000 | $722,682,000 | $-76,499,000 | $977,498,000 |
| Change In Prepaid Assets | $-212,351,000 | $-108,989,000 | $-106,382,000 | $-38,604,000 |
| Change In Inventory | $180,630,000 | $358,945,000 | $-105,388,000 | $-643,281,000 |
| Change In Receivables | $-178,516,000 | $-430,622,000 | $393,136,000 | $-493,027,000 |
| Other Non Cash Items | $-398,826,000 | $-320,927,000 | $-61,920,000 | $-49,547,000 |
| Stock Based Compensation | $556,521,000 | $574,197,000 | $469,490,000 | $501,572,000 |
| Depreciation And Amortization | $419,768,000 | $385,103,000 | $319,422,000 | $204,747,000 |
| Amortization Cash Flow | $94,837,000 | $74,887,000 | $42,635,000 | $2,577,000 |
| Depreciation | $324,931,000 | $310,216,000 | $276,787,000 | $202,170,000 |
| Gain Loss On Investment Securities | $-142,708,000 | $-21,292,000 | $-5,102,000 | $-125,017,000 |
| Net Foreign Currency Exchange Gain Loss | $-134,569,000 | $-60,824,000 | $-737,720,000 | $201,137,000 |
| Gain Loss On Sale Of PPE | $22,987,000 | $952,000 | $-60,000 | $709,000 |
| Net Income From Continuing Operations | $-78,621,000 | $-1,144,411,000 | $-2,170,469,000 | $-2,641,717,000 |
Fetched: 2026-02-02